Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
E: investor-relations@haleon.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,561.70 | 142.70 | -1.85% |
| CAC 40 | 6,821.59 | 278.83 | -3.93% |
| DAX 40 | 19,490.10 | 790.16 | -3.90% |
| Dow JONES (US) | 37,615.47 | 2,930.46 | -7.23% |
| FTSE 100 | 7,642.58 | 267.95 | -3.39% |
| HKSE | 20,264.49 | 136.81 | 0.68% |
| NASDAQ | 15,267.91 | 1,282.69 | -7.75% |
| Nikkei 225 | 31,714.03 | 1,298.55 | -3.93% |
| NZX 50 Index | 11,806.55 | 84.89 | -0.71% |
| S&P 500 | 4,977.73 | 5.04 | -0.10% |
| S&P/ASX 200 | 7,375.00 | 135.00 | -1.80% |
| SSE Composite Index | 3,186.81 | 41.26 | 1.31% |